Innoviva' Specialty Therapeutics Unit Signs Licensing Deal With Dr. Reddy's for Xacduro

MT Newswires Live06-16 20:21

Innoviva's (INVA) Innoviva Specialty Therapeutics unit said Tuesday it has signed an exclusive distribution and licensing deal with Dr. Reddy's Laboratorie (RDY) to develop and commercialize Xacduro to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Under the terms of the agreement, Dr. Reddy's will be responsible for the development, regulatory and commercialization activities in the licensed territories, which include South America, Central America, the Caribbean, Russia and the Commonwealth of Independent States.

Meanwhile, Innoviva Specialty Therapeutics will retain rights to Xacduro in all unlicensed territories, and is eligible to receive an upfront payment, regulatory and commercial milestone payments, and tiered royalties on net sales.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643752696?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-16 20:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643752696","market":"sh","top_or_hot":-1,"title":"Innoviva' Specialty Therapeutics Unit Signs Licensing Deal With Dr. Reddy's for Xacduro","media":"MT Newswires Live","content":"<html><body><p> Innoviva's (INVA) Innoviva Specialty <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> unit said Tuesday it has signed an exclusive distribution and licensing deal with Dr. Reddy's Laboratorie (RDY) to develop and commercialize Xacduro to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.</p><p>Under the terms of the agreement, Dr. Reddy's will be responsible for the development, regulatory and commercialization activities in the licensed territories, which include South America, Central America, the Caribbean, Russia and the Commonwealth of Independent States.</p><p>Meanwhile, Innoviva Specialty Therapeutics will retain rights to Xacduro in all unlicensed territories, and is eligible to receive an upfront payment, regulatory and commercial milestone payments, and tiered royalties on net sales.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innoviva' Specialty Therapeutics Unit Signs Licensing Deal With Dr. Reddy's for Xacduro</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnoviva' Specialty Therapeutics Unit Signs Licensing Deal With Dr. Reddy's for Xacduro\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-16 20:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Innoviva's (INVA) Innoviva Specialty <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> unit said Tuesday it has signed an exclusive distribution and licensing deal with Dr. Reddy's Laboratorie (RDY) to develop and commercialize Xacduro to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.</p><p>Under the terms of the agreement, Dr. Reddy's will be responsible for the development, regulatory and commercialization activities in the licensed territories, which include South America, Central America, the Caribbean, Russia and the Commonwealth of Independent States.</p><p>Meanwhile, Innoviva Specialty Therapeutics will retain rights to Xacduro in all unlicensed territories, and is eligible to receive an upfront payment, regulatory and commercial milestone payments, and tiered royalties on net sales.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4596","symbol_name":"哈里斯概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2643752696","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643752696","pubTimestamp":1781612478,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Innoviva's  Innoviva Specialty Therapeutics unit said Tuesday it has signed an exclusive distribution and licensing deal with Dr. Reddy's Laboratorie  to develop and commercialize Xacduro to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.Under the terms of the agreement, Dr. Reddy's will be responsible for the development, regulatory and commercialization activities in the licensed territories, which include South America, Central America, the Caribbean, Russia and the Commonwealth of Independent States.Meanwhile, Innoviva Specialty Therapeutics will retain rights to Xacduro in all unlicensed territories, and is eligible to receive an upfront payment, regulatory and commercial milestone payments, and tiered royalties on net sales.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4596":"哈里斯概念","LU0348744763.USD":"ALLIANZ ASIA PACIFIC INCOME \"A\" (USD) INC","INVA":"Innoviva, Inc.","BK4007":"制药","BK7016":"应用软件","BK4539":"次新股","BK4523":"印度概念","LENZ":"Therapeutics","BK4557":"大麻股","RDY":"如瑞迪博士","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","RDY.AU":"READYTECH HOLDINGS LTD"},"translate_title":"Innoviva的专业治疗部门与Dr.Reddy's签署Xacduro许可协议","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RDY.AU":1,"RDY":1,"INVA":1.5,"LENZ":1.5},"content_text":"Innoviva's (INVA) Innoviva Specialty Therapeutics unit said Tuesday it has signed an exclusive distribution and licensing deal with Dr. Reddy's Laboratorie (RDY) to develop and commercialize Xacduro to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.Under the terms of the agreement, Dr. Reddy's will be responsible for the development, regulatory and commercialization activities in the licensed territories, which include South America, Central America, the Caribbean, Russia and the Commonwealth of Independent States.Meanwhile, Innoviva Specialty Therapeutics will retain rights to Xacduro in all unlicensed territories, and is eligible to receive an upfront payment, regulatory and commercial milestone payments, and tiered royalties on net sales.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643752696","isCrawlerRequest":true}